3 Challenges when targeting inflammation in residual CV risk
Video navigation menu
- From a working hypothesis in 1994 to clinical trials 00:22
- Challenge 1: Identifying patients susceptible to beneficial effect of anti-inflammatory therapy: plaque fissure vs. erosion 04:49
- Challenge 2: Balance of benefits vs. harm of anti-inflammatory therapies 10:08:
- Challenge 3: Window of opportunity - plaque healing 11:42
This presentation by Filippo Crea is part of a series titled "Inflammation: The next therapeutic frontier in targeting cardiovascular risk". This series consists of an introduction, three lectures and a discussion in which four experts in this field will bring you up to date on the role of inflammation in atherosclerosis and how to translate findings from science and clinical trials into practice.
Filippo Crea is editor-in-chief of the European Heart Journal and affiliated with the Catholic University of the Sacred Heart in Rome, Italy.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant received from Novo Nordisk A/S.